文献速递淋巴瘤造血干细胞移植与细胞治疗

弥漫大B细胞淋巴瘤中延长CAR-T细胞采集至输注时间与较差结局相关

Prolonged chimeric antigen receptor-T apheresis to infusion time is associated with inferior outcomes in diffuse large B-cell lymphoma.
PubMed 文献 · Br J Haematol · 2025-08-11

该回顾性研究分析京都大学医院90例接受CAR-T治疗的复发/难治弥漫大B细胞淋巴瘤患者,中位采集至输注间隔66天(范围28-203天),按≥66天分为延迟组、<66天为非延迟组。多因素分析显示延迟输注是无进展生存的显著不良预后因素(aHR 3.13,95%CI 1.63-6.00,p=0.001),总生存亦较差(aHR 2.53,95%CI 1.29-4.96,p=0.007)。

要点

  • 中位采集至输注间隔66天(范围28-203天),延迟组定义为≥66天。
  • 延迟输注与无进展生存较差独立相关(aHR 3.13,95%CI 1.63-6.00,p=0.001)。
  • 延迟组总生存亦较差(aHR 2.53,95%CI 1.29-4.96,p=0.007)。

核心结论

  • 延长采集至输注时间与复发/难治弥漫大B细胞淋巴瘤患者CAR-T治疗后较差的無进展生存和总生存相关。

研究设计与样本

  • 回顾性分析京都大学医院接受CAR-T细胞治疗的复发/难治弥漫大B细胞淋巴瘤患者90例。
  • 中位采集至输注间隔66天(范围28-203天),按≥66天为延迟组、<66天为非延迟组。

主要发现

  • 输注时基线特征相似,但延迟组结外受累和稳定/进展疾病(SD/PD)等不良特征较少见。
  • 多因素分析显示延迟输注是无进展生存的显著负性预后因素(aHR 3.13;95%CI 1.63-6.00;p=0.001)。
  • 多因素分析中结外受累(aHR 2.39;p=0.004)、SD/PD(aHR 2.66;p=0.005)、大包块疾病(aHR 3.08;p=0.008)和tisa-cel治疗(aHR 5.26;p=0.001)亦为无进展生存的显著负性预后因素。
  • 延迟组总生存亦较差(aHR 2.53,95%CI 1.29-4.96;p=0.007)。

关键数值与推荐

  • 延迟输注定义:采集至输注间隔≥66天;非延迟组<66天。
  • 无进展生存:延迟组 vs 非延迟组 aHR 3.13(95%CI 1.63-6.00;p=0.001)。
  • 总生存:延迟组 vs 非延迟组 aHR 2.53(95%CI 1.29-4.96;p=0.007)。

临床怎么用

  • 作者认为,通过改进工作流程、提升机构能力以及避免对无应答者延长桥接治疗来缩短采集至输注间隔,可能改善结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chimeric antigen receptor (CAR) T-cell therapy is effective for relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL). However, delays between apheresis and infusion frequently occur due to limited facility capacity and prolonged bridging therapy, and the clinical impact of such delays remains uncertain. We retrospectively analysed R/R DLBCL patients who underwent CAR-T-cell therapy at Kyoto University Hospital. Among 90 patients, the median apheresis to infusion interval was 66 days (range, 28-203). Patients were categorized into delayed (≥66 days) and non-delayed (<66 days) groups. Baseline characteristics at infusion were similar, whereas adverse features such as extranodal involvement and stable/progressive disease (SD/PD) were less common in the delayed group. Multivariate analysis identified delayed infusion as a significant negative prognostic factor for progression-free survival (adjusted hazard ratio [aHR] 3.13; 95% confidence interval [CI] 1.63-6.00; p = 0.001), along with extranodal involvement (aHR 2.39; p = 0.004), SD/PD (aHR 2.66; p = 0.005), bulky disease (aHR 3.08; p = 0.008) and treatment with tisa-cel (aHR 5.26; p = 0.001). Overall survival was also inferior in the delayed group (aHR 2.53, 95% CI 1.29-4.96; p = 0.007). Minimizing apheresis to infusion interval through improved workflows, institutional capacity and avoiding prolonged bridging in non-responders may enhance outcomes.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Morimoto S, Jo T, Kitawaki T, et al. Prolonged chimeric antigen receptor-T apheresis to infusion time is associated with inferior outcomes in diffuse large B-cell lymphoma. Br J Haematol. 2025. PMID: 40785504. doi:10.1111/bjh.70090

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。